

Contents

1 Cardiovascular Therapeutics.....	1
Introduction.....	1
History of Cardiovascular Therapy.....	1
Overview of Cardiovascular Disease.....	2
Epidemiology of Cardiovascular Disease.....	2
Management of Acute Coronary Occlusive Disease.....	3
Limitations of Current Therapies for Myocardial Ischemic Disease.....	3
Angina Pectoris.....	4
Cardiomyopathies.....	4
Cardiac Arrhythmias.....	5
Congestive Heart Failure.....	6
Peripheral Arterial Disease.....	6
Cholesterol and Atherosclerosis.....	7
Familial Hypercholesterolemia.....	7
The Endothelium as a Target for Cardiovascular Therapeutics.....	8
Molecular Cardiology.....	8
Cardiogenomics.....	9
Cardioproteomics.....	9
Ion Channels and the Cardiovascular System.....	13
Role of Plasminogen Activator Inhibitor-1 in the Cardiovascular System.....	16
Biotechnology and Therapy of Cardiovascular Diseases.....	16
Chronopharmacotherapy of Cardiovascular Diseases.....	17
Cardioprotection.....	18
Management of Ischemic/Reperfusion Injury to the Heart.....	20
Beta Blockers as Cardioprotectives.....	21
Cardioprotective Effects of Growth Hormone.....	22
Cardioprotection by Blocking Complement Activation.....	22
Cardioprotection by Resveratrol.....	22
HDL-Mediated Pharmaceutical Cardioprotection.....	23
Nicorandil for Cardioprotection.....	23
Statins for Cardioprotection in Dilated Cardiac Myopathy.....	24

Role of Proteomics in Cardioprotection	24
Protection of the Blood Vessels	25
Important Advances in Cardiovascular Therapeutics	26
References.....	26
2 Drug Delivery to the Cardiovascular System	29
Introduction.....	29
Routes of Drug Delivery to the Cardiovascular System	29
Local Administration of Drugs to the Cardiovascular System	29
Intramyocardial Drug Delivery	29
Drug Delivery via Coronary Venous System.....	30
Intrapericardial Drug Delivery	31
Formulations for Drug Delivery to the Cardiovascular System.....	31
Sustained and Controlled Release.....	32
Methods of Administration of Proteins and Peptides	34
Targeted Drug Delivery to the Cardiovascular System.....	38
Immunotargeting of Liposomes to Activated Vascular Endothelial Cells.....	38
PEGylated Biodegradable Particles Targeted to Inflamed Endothelium.....	39
Devices for Cardiovascular Drug Delivery	40
Local Drug Delivery by Catheters	41
Micro-Infusion Catheters for Periarterial Injection	42
DDS in the Management of Ischemic Heart Disease.....	45
Drug Delivery for Cardiac Rhythm Disorders.....	47
Sustained and Controlled-Release Nitrate for Angina Pectoris	47
Vaccines Delivery for Hypertension	49
Drug Delivery in the Management of Pulmonary Hypertension	50
Anticoagulation in Cardiovascular Disease	51
Thrombolysis for Cardiovascular Disorders	53
Drug Delivery for Peripheral Arterial Disease.....	54
References.....	55
3 Role of Nitric Oxide in Cardiovascular Disorders.....	57
Introduction.....	57
Role of NO in Physiology of the Cardiovascular System.....	59
Hemoglobin, Oxygen, and Nitric Oxide	64
NO and Pulmonary Circulation	66
Role of NO in Pathomechanism of Cardiovascular Disorders.....	67
Oxidative Stress as a Cause of Cardiovascular Disease.....	67
Role of NO in Pathomechanism of Cardiovascular Diseases	67
NO and Atherosclerosis	70
Role of NO in Cardiopulmonary Disorders	71
Role of NO in Disturbances of Vasodilation.....	72
Role of NO in Hypercholesterolemia	72

Pulmonary Hypertension	73
NO and Systemic Hypertension.....	74
Coronary Artery Disease.....	76
Role of NO in the Pathophysiology of Angina Pectoris	76
Role of NO in the Pathophysiology of Congestive Heart Failure.....	77
Myocardial Ischemia/Reperfusion Injury	78
Role of NO in Management of Cardiovascular Disorders	80
Role of NO in Cardioprotection.....	80
Role of NO in the Management of Angina Pectoris	81
Role of NO in Therapy of Coronary Heart Disease	82
NO-Releasing Aspirin in Patients Undergoing CABG.....	83
NO-Based Therapies for Congestive Heart Failure	83
NO-Based Therapy for Management of Cardiogenic Shock.....	84
NO-Based Therapy for Cardiac Arrhythmias	84
Prophylaxis of Cardiovascular Disorders.....	85
Peripheral Vascular Disorders.....	86
References.....	88
4 Biomarkers of Cardiovascular Disorders	91
Introduction.....	91
Biomarkers of Cardiovascular Diseases.....	92
Methods for Identification of Cardiovascular Biomarkers.....	94
Application of Proteomics for Biomarkers of Cardiovascular Disease.....	94
Detection of Biomarkers of Myocardial Infarction in Saliva by a Nanobiochip	94
Metabolomic Technologies for Biomarkers of Myocardial Ischemia ...	95
Imaging Biomarkers of Cardiovascular Disease	95
Applications of Biomarkers of Cardiovascular Disease	97
Biomarkers for Ischemic Heart Disease and Myocardial Infarction.....	97
Biomarkers of Congestive Heart Failure.....	103
Biomarkers for Atherosclerosis	108
Biomarkers of Risk Factors for Coronary Heart Disease	112
Biomarkers for Pulmonary Arterial Hypertension.....	114
Genetic Biomarkers for Cardiovascular Disease	116
Multiple Biomarkers for Prediction of Death from Cardiovascular Disease	121
Role of Biomarkers in the Management of Cardiovascular Disease	122
Role of Biomarkers in the Diagnosis/Prognosis of Myocardial Infarction	122
Role of Biomarkers in the Prevention of Cardiovascular Disease	122
Molecular Signature Analysis in Management of Cardiovascular Diseases	123
C-Reactive Protein as Biomarker of Response to Statin Therapy	124

Role of Circulating Biomarkers and Mediators of Cardiovascular Dysfunction	125
Use of Protein Biomarkers for Monitoring Acute Coronary Syndromes	125
Use of Biomarkers for Prognosis of Recurrent Atrial Fibrillation	126
Use of Multiple Biomarkers for Monitoring of Cardiovascular Disease.....	126
Use of Biomarkers in the Management of Peripheral Arterial Disease.....	127
Use of Biomarkers in the Management of Hypertension.....	127
Future Prospects for Cardiovascular Biomarkers	128
Cardiovascular Biomarker Consortium.....	128
Systems Approach to Biomarker Research in Cardiovascular Disease.....	128
References.....	129
5 Molecular Diagnosis of Cardiovascular Disorders	133
Introduction.....	133
Basics of Molecular Diagnosis	133
Molecular Imaging of Cardiovascular Disorders.....	134
Genetic Cardiovascular Disorders	135
Coronary Heart Disease	135
Cardiomyopathy.....	136
Familial Hypertrophic Cardiomyopathy	136
Idiopathic Dilated Cardiomyopathy.....	137
Cardiac Arrhythmias.....	137
Long Q-T Syndrome	137
Familial Atrial Fibrillation.....	138
Idiopathic Ventricular Fibrillation.....	138
Early Detection of Congestive Heart Failure.....	139
Genetic Testing in Hypertension.....	139
Gene Mutations and Disturbances of Blood Lipids.....	140
Familial Dyslipoproteinemias.....	140
Hypercholesterolemia	140
Gene Mutations Associated with Thrombotic Disorders.....	141
Factor V Leiden Mutation.....	141
Pulmonary Embolism.....	142
Companies Involved in Cardiovascular Molecular Diagnosis	142
References.....	144
6 Nanobiotechnology in Cardiovascular Disorders	145
Introduction.....	145
Nanotechnology-Based Cardiovascular Diagnosis	146
Nanobiotechnology for Molecular Diagnostics	146
Nanosensors	147

Use of Magnetic Nanoparticles as MRI Contrast Agents for Cardiac Disorders	148
Use of Perfluorocarbon Nanoparticles in Cardiovascular Disorders	148
Cardiac Monitoring in Sleep Apnea	148
Detection and Treatment of Atherosclerotic Plaques in the Arteries.....	149
Monitoring for Disorders of Blood Coagulation	149
Nanotechnology-Based Therapeutics for Cardiovascular Diseases.....	150
Nanolipoblockers for Atherosclerotic Arterial Plaques	150
Nanotechnology-Based Drug Delivery in Cardiovascular Diseases.....	150
Antirestenosis Drugs Encapsulated in Biodegradable Nanoparticles....	152
Controlled Delivery of Nanoparticles to Injured Vasculature.....	152
IGF-1 Delivery by Nanofibers to Improve Cell Therapy for Myocardial Infarction.....	152
Injectable Peptide Nanofibers for Myocardial Ischemia.....	153
Liposomal Nanodevices for Targeted Cardiovascular Drug Delivery ...	153
Low Molecular Weight Heparin-Loaded Polymeric Nanoparticles.....	154
Nanoparticles for Cardiovascular Imaging and Targeted Drug Delivery	154
Nanofiber-Based Scaffolds with Drug-Release Properties	155
Nanotechnology Approach to the Vulnerable Plaque as Cause of Cardiac Arrest.....	155
Nanotechnology for Regeneration of the Cardiovascular System	156
References	157
7 Cell Therapy for Cardiovascular Disorders	159
Introduction.....	159
Types of Cell Therapy for Cardiovascular Disorders.....	159
Cell-Mediated Immune Modulation for Chronic Heart Disease.....	160
Human Cardiovascular Progenitor Cells.....	161
Inducing the Proliferation of Cardiomyocytes.....	162
Role of the SDF-1-CXCR4 Axis in Stem Cell Therapies for Myocardial Ischemia	163
Role of Splenic Myocytes in Repair of the Injured Heart.....	163
Reprogramming of Fibroblasts into Functional Cardiomyocytes.....	164
Small Molecules to Enhance Myocardial Repair by Stem Cells	164
Cell Therapy for Atherosclerotic Coronary Artery Disease	165
MyoCell™ (Bioheart).....	165
Cardiac Stem Cells.....	166
Cardiomyocytes Derived from Epicardium	167
Methods of Delivery of Cells to the Heart.....	168
Cellular Cardiomyoplasty	168
IGF-1 Delivery by Nanofibers to Improve Cell Therapy for MI	168
Noninvasive Delivery of Cells to the Heart by Morph®guide Catheter	169
Cell Therapy for Cardiac Revascularization	169

Transplantation of Cardiac Progenitor Cells for Revascularization of Myocardium.....	169
Stem Cells to Prevent Restenosis After Coronary Angioplasty.....	170
Role of Cells in Cardiac Tissue Repair.....	171
Modulation of Cardiac Macrophages for Repair of Infarct	171
Transplantation of Myoblasts for Myocardial Infarction.....	171
Patching Myocardial Infarction with Fibroblast Culture	172
Cardiac Repair with Myoendothelial Cells from Skeletal Muscle	173
Myocardial Tissue Engineering	173
Role of Stem Cells in Repair of the Heart	175
Role of Stem Cells in Cardiac Regeneration Following Injury	175
Cardiomyocytes Derived from Adult Skin Cells	175
Cardiomyocytes Derived from ESCs.....	176
Studies to Identify Subsets of Progenitor Cells Suitable for Cardiac Repair.....	176
Technologies for Preparation of Stem Cells for Cardiovascular Therapy.....	178
Role of ESCs in Repair of the Heart.....	180
Transplantation of Stem Cells for Acute Myocardial Infarction	181
Stem Cell Therapy for Cardiac Regeneration.....	188
Transplantation of Genetically Modified Cells.....	191
Transplantation of Genetically Modified MSCs	191
Transplantation of Cells Secreting Vascular Endothelial Growth Factor	191
Transplantation of Genetically Modified Bone Marrow Stem Cells	192
Cell Transplantation for Congestive Heart Failure	192
Myoblasts for Treatment of Congestive Heart Failure.....	193
Injection of Adult Stem Cells for Congestive Heart Failure.....	193
AngioCell Gene Therapy for Congestive Heart Failure	194
Stem Cell Therapy for Dilated Cardiac Myopathy	195
Role of Cell Therapy in Cardiac Arrhythmias	196
Atrioventricular Conduction Block.....	196
Ventricular Tachycardia	198
Prevention of Myoblast-Induced Arrhythmias by Genetic Engineering.....	198
ESCs for Correction of Congenital Heart Defects.....	199
Cardiac Progenitors Cells for Treatment of Heart Disease.....	199
Autologous Stem Cells for Chronic Myocardial Ischemia	200
Role of Cells in Cardiovascular Tissue Engineering	201
Construction of Blood Vessels with Cells.....	201
Targeted Delivery of Endothelial Progenitor Cells Labeled with Nanoparticles	202
Fetal Cardiomyocytes Seeding in Tissue-Engineered Cardiac Grafts ...	202
UCB Progenitor Cells for Engineering Heart Valves.....	202
Cell Therapy for Peripheral Vascular Disease	203

ALD-301	203
Cell/Gene Therapy for PVD	203
Colony Stimulating Factors for Enhancing Peripheral Blood Stem Cells	204
Intramuscular Autologous Bone Marrow Cells	204
Vascular Repair Cell	205
Clinical Trials of Cell Therapy in Cardiovascular Disease.....	205
Mechanism of the Benefit of Cell Therapy for Heart Disease.....	211
A Critical Evaluation of Cell Therapy for Heart Disease	211
Current Status of Cell Therapy for Cardiovascular Disease	212
Future Directions for Cell Therapy of CVD.....	212
Prospects of Adult Stem Cell Therapy for Repair of Heart	213
Regeneration of Cardiomyocytes Without Use of Cardiac Stem Cells	214
References.....	214
8 Gene Therapy for Cardiovascular Disorders.....	219
Introduction.....	219
Techniques of Gene Transfer to the Cardiovascular System	220
Direct Plasmid Injection into the Myocardium.....	220
Catheter-Based Systems for Vector Delivery.....	221
Ultrasound Microbubbles for Cardiovascular Gene Delivery.....	221
Vectors for Cardiovascular Gene Therapy	221
Hypoxia-Regulated Gene Therapy for Myocardial Ischemia.....	224
Angiogenesis and Gene Therapy of Ischemic Disorders.....	225
Therapeutic Angiogenesis with Vascular Endothelial Growth Factor Therapy	226
Gene Painting for Delivery of Targeted Gene Therapy to the Heart.....	226
Gene Delivery to Vascular Endothelium.....	227
Targeted Plasmid DNA Delivery to the Cardiovascular System with Nanoparticles	227
Gene Therapy for Genetic Cardiovascular Disorders	229
Genetic Disorders Predisposing to Atherosclerosis	229
Gene Therapy of Familial Hypercholesterolemia	229
Apolipoprotein E Deficiency	231
Hypertension	232
Genetic Factors for Myocardial Infarction.....	233
Gene Therapy for Acquired Cardiovascular Diseases	233
Coronary Artery Disease with Angina Pectoris.....	233
Gene Therapy for Improving Long-Term CABG Patency Rates.....	234
Ischemic Heart Disease with Myocardial Infarction	234
Congestive Heart Failure.....	237
Gene Therapy for Cardiac Arrhythmias.....	240
Gene Therapy and Heart Transplantation	242
Gene Therapy for Peripheral Arterial Disease.....	243

Maintaining Vascular Patency After Surgery.....	245
Antisense Therapy for Cardiovascular Disorders	245
Antisense Therapy for Hypertension	246
Antisense Therapy for Hypercholesterolemia	247
Antisense Therapy for Preventing Occlusion of Venous Grafts in CABG	248
RNAi for Cardiovascular Disorders.....	248
RNAi for Hypercholesterolemia	249
microRNA and the Cardiovascular System	250
Future Prospects of Gene Therapy of Cardiovascular Disorders.....	253
Companies Involved in Gene Therapy of Cardiovascular Disorders.....	255
References.....	256
9 Coronary Angioplasty and Drug-Eluting Stents.....	259
Introduction.....	259
Percutaneous Transluminal Coronary Angioplasty	259
Stents.....	260
Restenosis	260
Pathomechanism	261
Treatment.....	262
Role of NO in the Management of Coronary Restenosis	262
Carbon Monoxide Inhalation for Preventing Restenosis	264
Antisense Approaches for Prevention of Restenosis After Angioplasty	265
miRNA-Based Approach for Restenosis Following Angioplasty.....	265
Gene Therapy to Prevent Restenosis After Angioplasty.....	266
Drug Delivery Devices for Restenosis	269
Local Drug Delivery by Catheter.....	270
Absorbable Metal Stents	270
Drug-Eluting Stents	271
Various Types of DES	271
Novel Technologies for DES	274
Nanotechnology-Based Stents	278
Restenosis After Percutaneous Coronary Angioplasty	278
The Ideal DES.....	282
Companies Developing Drug-Eluting Stents	283
Clinical Trials of Drug-Eluting Stents	284
Comparison of DES with Competing Technologies	291
Cost-Effectiveness of DES.....	297
Safety Issues of DES.....	298
Regulatory Issues of DES	303
Future Prospects for Treatment of Restenosis by DES.....	305
Future Role of DES in Management of Cardiovascular Diseases	305
Stent Cost and Marketing Strategies.....	306

Contents	xxi
Improvements in Stent Technology	307
DES Versus Drug-Eluting Balloons.....	308
References.....	308
10 Personalized Cardiology.....	315
Introduction to Personalized Medicine.....	315
Role of Diagnostics in Personalized Management of Cardiovascular Disease	316
Testing in Coronary Heart Disease	316
SNP Genotyping in Cardiovascular Disorders.....	316
Cardiovascular Disorders with a Genetic Component	317
Gene Variant as a Risk Factor for Sudden Cardiac Death	318
KIF6 Gene Test as a Guide to Management of Congestive Heart Failure.....	320
SNP Chip for Study of Cardiovascular Diseases	321
Pharmacogenomics of Cardiovascular Disorders.....	321
Modifying the Genetic Risk for Myocardial Infarction.....	321
Management of Heart Failure.....	322
β -Blockers.....	322
Bucindolol.....	323
BiDil.....	323
Management of Hypertension	324
Pharmacogenomics of Diuretic Drugs	324
Pharmacogenomics of ACE Inhibitors.....	325
Management of Hypertension by Personalized Approach.....	326
Prediction of Antihypertensive Activity of Rostafuroxin	327
Pharmacogenetics of Lipid-Lowering Therapies	328
Polymorphisms in Genes Involved in Cholesterol Metabolism	328
Role of eNOS Gene Polymorphisms.....	329
The STRENGTH Study	330
Personalized Management of Women with Hyperlipidemia.....	331
Thrombotic Disorders.....	331
Factor V Leiden Mutation.....	332
Anticoagulant Therapy.....	332
Antiplatelet Therapy.....	333
Nanotechnology-Based Personalized Therapy of Cardiovascular Diseases	333
Project euHeart for Personalized Management of Heart Disease.....	334
Concluding Remarks	335
References.....	335
Index.....	337